Form 10-Q - Quarterly report [Sections 13 or 15(d)]

S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

ImmunityBio (NASDAQ:IBRX)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more ImmunityBio Charts.

ImmunityBio (NASDAQ:IBRX)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more ImmunityBio Charts.

ImmunityBio Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 4 January 2025 (2 days ago) • Edgar (US Regulatory)

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering
Friday 13 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Form 424B5 - Prospectus [Rule 424(b)(5)]
Thursday 12 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 11 December 2024 (4 weeks ago) • Edgar (US Regulatory)

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
Wednesday 11 December 2024 (4 weeks ago) • Business Wire

Form 8-K - Current report
Wednesday 11 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Wednesday 11 December 2024 (4 weeks ago) • Edgar (US Regulatory)

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
Wednesday 11 December 2024 (4 weeks ago) • Business Wire

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
Friday 22 November 2024 (1 month ago) • PR Newswire (US)

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements
Wednesday 20 November 2024 (2 months ago) • PR Newswire (US)

Form 8-K - Current report
Wednesday 20 November 2024 (2 months ago) • Edgar (US Regulatory)

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
Wednesday 20 November 2024 (2 months ago) • Business Wire

More ImmunityBio Inc News Articles

Woodside Petroleum

Sterling vs AUD

S&P ASX 300 Metals and M...

Australia And New Zealan...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions